Skip to content

OxSonics Wins The Gold Award at the 2019 Tech Tour Contest Grand Final

OxSonics Wins The Gold Award at the 2019 Tech Tour Contest Grand Final

Oxford, UK – 10th December 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that from over 2,500 companies it has been judged the ultimate winner of the European-wide Healthtech 2019 Tech Tour Contest Final.

The 13th edition of the Tech Tour Contest Final 2019 – Europe’s leading network and investment event for high-growth technological start-ups, venture capital investors and technological corporations took place on 9-10 December 2019 in Essen, Germany.

The 125 presenting companies were invited as the ‘top-rated companies’ of the Tech Tour European Venture Contest, that took place throughout 2019 in 20 regional or sector–focused qualifying events involving over 2,500 individual companies. These top 125 were first judged by panels of investors to find a shortlist of 17 from 125 and then through a second round of “pitch battle” in front of an enlarged judging panel to find the ultimate winner in healthtech. OxSonics came top in all stages of the competition and secured 1st Place GOLD in the healthtech category.

Colin Story, CEO, commented: “This is a truly amazing result for OxSonics – to be judged the winner amongst so many healthtech companies across the whole of Europe is something to be truly proud of. This success is testament to the world leading and highly innovative technology OxSonics is developing and the first-class R&D, regulatory and commercial teams at OxSonics taking this technology forward for the benefit of patients. We are truly delighted by this achievement.”

The Tech Tour press release can be viewed here.

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit:

About TechTour

Founded in 1998, Tech Tour is a unique cross-border platform for growing and emerging innovative tech companies on their way to investment and funding – _from the idea to the success story. The platform supports innovative companies and their projects through online community space and in person at 25 networking events that we organise each year. Tech Tour is well known in the venture capital market with its 20-years of experience across Europe and the Middle East, and planning to enlarge our scope of work to China. For more information please visit: